Additionally, the latest National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines for Breast Cancer (2025, Version 2) recommend inavolisib in combination with palbociclib and fulvestrant as a first‐line treatment for patients with advanced PIK3CA‐mutated, HR‐positive/HER2‐negative breast cancer that relapse within 12 months during or after adjuvant endocrine therapy (Category I) [45]. Here, PIK3CA is linked to breast cancer.